{"id":"cdp-choline","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL920","moleculeType":"Small molecule","molecularWeight":"104.17"},"_dailymed":{"setId":"2b7ee28f-474e-414b-bf74-8b2baf382947","title":"HGH COMPLEX (ARGININE PYROGLUTAMATE, COLEUS FORSKOHLII, GLUTAMINE, GLYCINE, LYSINE, MUCUNA PRURIENS, ORNITHINE ALPHA-KETOGLUTARATE, TRIBULUS TERRESTRIS, TYROSINE, CDP-CHOLINE, GABA) SPRAY [PROBLEN]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CDP-Choline (cytidine diphosphate choline) is converted to phosphatidylcholine, a major component of neuronal cell membranes. It increases acetylcholine production and promotes membrane phospholipid synthesis, thereby supporting neuronal function and protecting against neurodegeneration. This mechanism supports cognitive function and neuroprotection in conditions affecting the central nervous system.","oneSentence":"CDP-Choline is a precursor to phosphatidylcholine that increases acetylcholine synthesis and enhances cell membrane integrity in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:50:11.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cognitive decline and memory impairment"},{"name":"Stroke recovery and neuroprotection"},{"name":"Age-related cognitive disorders"}]},"trialDetails":[{"nctId":"NCT06029894","phase":"NA","title":"Improving Sleep and AD Biomarkers","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-12-15","conditions":"Mild Cognitive Impairment, Alzheimer Disease","enrollment":100},{"nctId":"NCT05008588","phase":"PHASE1, PHASE2","title":"Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct","status":"ACTIVE_NOT_RECRUITING","sponsor":"PT. Prodia Stem Cell Indonesia","startDate":"2022-05-30","conditions":"Ischemic Stroke","enrollment":15},{"nctId":"NCT07322965","phase":"NA","title":"Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma","status":"RECRUITING","sponsor":"Institut Catala de Retina","startDate":"2025-04-01","conditions":"Glaucoma, Primary Open Angle Glaucoma (POAG), Neuroprotection","enrollment":108},{"nctId":"NCT07333339","phase":"","title":"A Brain-Computer Interface-Based Attention Training Program Compared With Methylphenidate and Citicoline","status":"COMPLETED","sponsor":"Uludag University","startDate":"2025-02-01","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Brain Computer Interface","enrollment":174},{"nctId":"NCT07319117","phase":"NA","title":"Evaluation of the Impact of a Nutritional Formulation on Cognitive Performance Following Stress Exposure.","status":"RECRUITING","sponsor":"Leeds Beckett University","startDate":"2025-12-15","conditions":"Cognitive Assessment, Working Memory, Executive Function (Cognition)","enrollment":40},{"nctId":"NCT04784234","phase":"NA","title":"Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin","status":"TERMINATED","sponsor":"Wills Eye","startDate":"2021-02-01","conditions":"Primary Open Angle Glaucoma","enrollment":12},{"nctId":"NCT05200208","phase":"NA","title":"Improving Sleep and Cognition in Alzheimer's Disease","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-07-27","conditions":"Alzheimer Disease","enrollment":20},{"nctId":"NCT05870111","phase":"PHASE2","title":"Citicoline in Youth Alcohol Use Disorder","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2024-10-01","conditions":"Alcohol Use Disorder","enrollment":56},{"nctId":"NCT06333236","phase":"NA","title":"Effect of Kron (Citicoline and Nicotinamide Oral Solution) on Patients With Open-angle Glaucoma","status":"COMPLETED","sponsor":"ASST Santi Paolo e Carlo","startDate":"2025-04-10","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT07089238","phase":"NA","title":"Evaluate the Effects of Citicoline on Mood in Healthy Adults","status":"RECRUITING","sponsor":"Kirin Holdings Company, Limited","startDate":"2025-07-31","conditions":"Healthy","enrollment":90},{"nctId":"NCT06906848","phase":"NA","title":"Evaluate the Effects of Citicoline on Cognitive Performance in Healthy Adults","status":"COMPLETED","sponsor":"Kirin Holdings Company, Limited","startDate":"2024-11-20","conditions":"Healthy, Cognitive Performance","enrollment":90},{"nctId":"NCT04422743","phase":"NA","title":"Effect of Citicoline/Homotaurine on PERG in Primary Open Angle Glaucoma","status":"TERMINATED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2018-01-25","conditions":"Glaucoma","enrollment":63},{"nctId":"NCT06431113","phase":"PHASE3","title":"Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2024-01-27","conditions":"Glaucoma, Neuroprotection","enrollment":40},{"nctId":"NCT04967157","phase":"NA","title":"Cognitive Effects of Citicoline on Attention in Healthy Mean and Women","status":"COMPLETED","sponsor":"Kirin Holdings Company, Limited","startDate":"2021-09-08","conditions":"Healthy","enrollment":148},{"nctId":"NCT05881135","phase":"PHASE1, PHASE2","title":"Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2023-06-06","conditions":"COVID-19","enrollment":80},{"nctId":"NCT06890962","phase":"NA","title":"Citicoline Dose on Energy Drink Efficacy","status":"COMPLETED","sponsor":"Nathaniel Jenkins","startDate":"2023-06-09","conditions":"Cognitive Performance, Gaming Performance, Blood Pressure","enrollment":34},{"nctId":"NCT05315206","phase":"NA","title":"Multimodal Morpho-functional Study in Glaucoma Patients-Citicoline Oral Solution","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2022-01-25","conditions":"Primary Open Angle Glaucoma","enrollment":29},{"nctId":"NCT01338389","phase":"NA","title":"Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2012-06-25","conditions":"Uveal Melanoma","enrollment":21},{"nctId":"NCT02582905","phase":"PHASE4","title":"Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders","status":"COMPLETED","sponsor":"Sherwood Brown, MD, PhD","startDate":"2016-05","conditions":"Alcohol Use Disorder, Bipolar Disorder, Schizoaffective Disorder Bipolar Type","enrollment":96},{"nctId":"NCT06210646","phase":"PHASE3","title":"Citicoline in Ischemic Stroke, a Randomized Trial","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-12-29","conditions":"Ischemic Stroke","enrollment":800},{"nctId":"NCT06522581","phase":"PHASE1","title":"Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy","status":"RECRUITING","sponsor":"Armed Forces Hospital, Pakistan","startDate":"2024-01-01","conditions":"Hypoxic Ischemic Encephalopathy of Newborn","enrollment":200},{"nctId":"NCT03430817","phase":"PHASE4","title":"Citicholine-Amantadine Trial in Traumatic Brain Injury","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-12-07","conditions":"Intensive Care Unit","enrollment":45},{"nctId":"NCT06355765","phase":"","title":"Citicoline & Antioxidants in Glaucoma","status":"COMPLETED","sponsor":"University of Naples","startDate":"2022-01-10","conditions":"Glaucoma, Open-Angle","enrollment":60},{"nctId":"NCT05710198","phase":"PHASE3","title":"Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma","status":"RECRUITING","sponsor":"Omikron Italia S.r.l.","startDate":"2023-12-11","conditions":"Glaucoma, Open-Angle","enrollment":1000},{"nctId":"NCT03758118","phase":"NA","title":"Citicoline in Non-Arteritic Ischemic Optic Neuropathy","status":"COMPLETED","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2017-02-20","conditions":"Non-arteritic Ischemic Optic Neuropathy","enrollment":40},{"nctId":"NCT04499157","phase":"NA","title":"Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2020-08-01","conditions":"Open-angle Glaucoma, Visual Field","enrollment":100},{"nctId":"NCT05000190","phase":"NA","title":"Acute and Chronic Effect of 250 mg Citicoline Consumption on Attention in Adults: A Randomized Trial","status":"COMPLETED","sponsor":"PepsiCo Global R&D","startDate":"2021-09-13","conditions":"Attention","enrollment":104},{"nctId":"NCT02197104","phase":"PHASE2","title":"Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2015-01","conditions":"Fragile X Tremor/Ataxia Syndrome","enrollment":10},{"nctId":"NCT05527106","phase":"NA","title":"Evaluation of the Effect of Citicoline and Docosahexaenoic Acid (DHA) on the Visual Function of Patients With Glaucoma","status":"COMPLETED","sponsor":"Institut Catala de Retina","startDate":"2015-03-12","conditions":"Glaucoma","enrollment":73},{"nctId":"NCT02630069","phase":"PHASE2","title":"CDP-choline Treatment in ATS Users","status":"UNKNOWN","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2015-03","conditions":"Substance Use Disorders","enrollment":160},{"nctId":"NCT04790188","phase":"NA","title":"Effect of a Nootropic on the Cognitive Performance in Young Adults","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2021-04-01","conditions":"Cognitive Change","enrollment":25},{"nctId":"NCT04046809","phase":"NA","title":"Study of Neurotidine® Intake on Life Quality of Patients With Glaucoma","status":"COMPLETED","sponsor":"Omikron Italia S.r.l.","startDate":"2019-02-13","conditions":"Glaucoma","enrollment":155},{"nctId":"NCT05154903","phase":"PHASE3","title":"Citicoline in Ischemic Stroke","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2021-07-22","conditions":"Acute Ischemic Stroke","enrollment":200},{"nctId":"NCT01502813","phase":"NA","title":"Citicoline, Creatine, and Omega-3 Effects in Middle Age Women","status":"COMPLETED","sponsor":"Deborah Yurgelun-Todd","startDate":"2012-02-01","conditions":"Cognitive Benefits","enrollment":40},{"nctId":"NCT02984813","phase":"PHASE1","title":"Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy","status":"TERMINATED","sponsor":"The New York Eye & Ear Infirmary","startDate":"2016-04-15","conditions":"Open-angle Glaucoma, Diabetic Retinopathy","enrollment":21},{"nctId":"NCT04802785","phase":"PHASE2, PHASE3","title":"The Impact of Air Travel on Passenger Cognitive Functions","status":"UNKNOWN","sponsor":"Dinara Zhumanbayeva","startDate":"2021-06","conditions":"Air Travel","enrollment":50},{"nctId":"NCT00404729","phase":"PHASE4","title":"Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases","status":"COMPLETED","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2005-02-28","conditions":"Glaucoma, Optic Neuropathy, Ischemic, Visual Pathway Disorder","enrollment":60},{"nctId":"NCT03444662","phase":"NA","title":"The Combination Effect of Citicoline and Omega-3","status":"COMPLETED","sponsor":"Kyowa Hakko Bio Co., Ltd.","startDate":"2018-06-12","conditions":"Healthy","enrollment":70},{"nctId":"NCT04020705","phase":"NA","title":"The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma","status":"COMPLETED","sponsor":"Istituto di Ricerca Neuroftalmologia S.r.l.","startDate":"2015-09-22","conditions":"Glaucoma","enrollment":90},{"nctId":"NCT04009980","phase":"NA","title":"Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2015-09-23","conditions":"Diabetic Retinopathy","enrollment":20},{"nctId":"NCT04003090","phase":"NA","title":"Citicoline Concentration in Human Vitreous","status":"COMPLETED","sponsor":"Istituto di Ricerca Neuroftalmologia S.r.l.","startDate":"2018-03-21","conditions":"Neurodegenerative Diseases","enrollment":26},{"nctId":"NCT03966170","phase":"PHASE3","title":"Citicoline as Neuroprotector in Preterm","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2019-05-01","conditions":"Pre-Term","enrollment":40},{"nctId":"NCT03949049","phase":"PHASE3","title":"Citicoline as Neuroprotector in Neonates Exposed to Hypoxia","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2019-02-01","conditions":"Neonatal Hypoxia","enrollment":40},{"nctId":"NCT02705066","phase":"NA","title":"Citicoline Effects on Cortical Membrane Structure and Function","status":"COMPLETED","sponsor":"Kyowa Hakko Bio Co., Ltd.","startDate":"2016-03","conditions":"Healthy","enrollment":61},{"nctId":"NCT03906513","phase":"NA","title":"Evaluation of the Efficacy of OMK2 in Recovering Corneal Neural Damage in Patients With Diabetes","status":"COMPLETED","sponsor":"University of Milan","startDate":"2017-05-03","conditions":"Cornea","enrollment":30},{"nctId":"NCT03369925","phase":"NA","title":"Cognitive Effects of Citicoline in Men and Women With Age-Associated Memory Impairment","status":"COMPLETED","sponsor":"Kyowa Hakko Bio Co., Ltd.","startDate":"2018-01-02","conditions":"Healthy","enrollment":100},{"nctId":"NCT01582113","phase":"EARLY_PHASE1","title":"Cognizin Citicoline Dosing in a Healthy Adolescent Male Population","status":"COMPLETED","sponsor":"Deborah Yurgelun-Todd","startDate":"2012-06","conditions":"Neurocognitive Improvement","enrollment":84},{"nctId":"NCT02074735","phase":"PHASE4","title":"Citicoline for Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-04","conditions":"Alcohol Dependence","enrollment":62},{"nctId":"NCT02248233","phase":"PHASE4","title":"Nimodipine for Treating Acute Massive Cerebral Infarction","status":"COMPLETED","sponsor":"Fengtian Hospital","startDate":"2014-10","conditions":"Cerebral Infarction","enrollment":72},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT00619723","phase":"PHASE4","title":"Citicoline for Bipolar 1 Disorder and Cocaine Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2008-04","conditions":"Bipolar Disorder, Cocaine Dependence","enrollment":130},{"nctId":"NCT02840591","phase":"PHASE4","title":"Ramelteon and Citicoline for Delirium","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-07","conditions":"Delirium","enrollment":""},{"nctId":"NCT03046693","phase":"PHASE4","title":"Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)","status":"COMPLETED","sponsor":"Valen Chia","startDate":"2017-01-16","conditions":"Non-arteritic Anterior Ischemic Optic Neuropathy","enrollment":38},{"nctId":"NCT00727246","phase":"PHASE2","title":"CDP-Choline and Working Memory After TBI: A Neuroimaging Study","status":"COMPLETED","sponsor":"Patricia M. Arenth","startDate":"2009-03","conditions":"Brain Injuries","enrollment":19},{"nctId":"NCT03181646","phase":"PHASE3","title":"Role of Citicoline in Treatment of Newborns With Hypoxic Ischemic Encephalopathy","status":"UNKNOWN","sponsor":"Armed Forces Hospital, Pakistan","startDate":"2017-06-15","conditions":"Hypoxic-Ischemic Encephalopathy","enrollment":50},{"nctId":"NCT02362984","phase":"PHASE3","title":"DLBS1033 for the Treatment of Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Dexa Medica Group","startDate":"2014-10","conditions":"Acute Ischemic Stroke","enrollment":9},{"nctId":"NCT02823106","phase":"PHASE1","title":"Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response","status":"WITHDRAWN","sponsor":"Justin Fraser","startDate":"2016-08","conditions":"Ischemic Stroke","enrollment":""},{"nctId":"NCT00950352","phase":"PHASE3","title":"Citicoline Treatment of Methamphetamine Dependence","status":"COMPLETED","sponsor":"Perry Renshaw","startDate":"2010-01","conditions":"Methamphetamine Dependence","enrollment":104},{"nctId":"NCT01515917","phase":"NA","title":"Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)","status":"WITHDRAWN","sponsor":"Deborah Yurgelun-Todd","startDate":"2013-11","conditions":"Traumatic Brain Injury, Substance Abuse, Substance Dependence","enrollment":""},{"nctId":"NCT00158249","phase":"PHASE2","title":"Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2009-09","conditions":"Marijuana Abuse","enrollment":21},{"nctId":"NCT00223236","phase":"PHASE3","title":"Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2010-07","conditions":"Mania, Hypomania, Cocaine Abuse","enrollment":44},{"nctId":"NCT01591759","phase":"PHASE2","title":"A Pilot Trial of Citicoline in Individuals With Mild Traumatic Brain Injury (mTBI)","status":"WITHDRAWN","sponsor":"Mclean Hospital","startDate":"2012-04","conditions":"Traumatic Brain Injury","enrollment":""},{"nctId":"NCT02088983","phase":"PHASE2","title":"Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizophrenia","status":"UNKNOWN","sponsor":"University of Ottawa","startDate":"2014-04","conditions":"First Episode Schizophrenia","enrollment":40},{"nctId":"NCT01400035","phase":"","title":"Chinese Assessment for Vinpocetine In Neurology","status":"COMPLETED","sponsor":"Shanghai Rxmidas Pharmaceuticals Co. Ltd.","startDate":"2010-05","conditions":"Cerebral Infarction","enrollment":610},{"nctId":"NCT00377299","phase":"NA","title":"A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2006-10","conditions":"Amphetamine Abuse, Amphetamine Dependence, Bipolar Disorder","enrollment":60},{"nctId":"NCT00545662","phase":"PHASE3","title":"Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)","status":"TERMINATED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2007-07","conditions":"Traumatic Brain Injury","enrollment":1213},{"nctId":"NCT01007539","phase":"PHASE3","title":"Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-11","conditions":"Methamphetamine Dependence","enrollment":31},{"nctId":"NCT00331890","phase":"PHASE3","title":"ICTUS Study: International Citicoline Trial on Acute Stroke","status":"TERMINATED","sponsor":"Ferrer Internacional S.A.","startDate":"2006-10","conditions":"Acute Stroke, Cerebral Infarction","enrollment":2298},{"nctId":"NCT01556854","phase":"","title":"Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"yongjun wang","startDate":"2011-07","conditions":"Acute Ischemic Stroke","enrollment":20000},{"nctId":"NCT01388738","phase":"PHASE3","title":"Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.","status":"COMPLETED","sponsor":"Clinical Institute of the Brain, Russia","startDate":"2011-01","conditions":"Stroke","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1052,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Citicoline","Cytidine 5'-diphosphocholine"],"phase":"marketed","status":"active","brandName":"CDP-Choline","genericName":"CDP-Choline","companyName":"Patricia M. Arenth","companyId":"patricia-m-arenth","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CDP-Choline is a precursor to phosphatidylcholine that increases acetylcholine synthesis and enhances cell membrane integrity in the brain. Used for Cognitive decline and memory impairment, Stroke recovery and neuroprotection, Age-related cognitive disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}